For the Inventor, By the Inventor

Enter assignee name

Marseille, France

Innate Pharma, S.a.

USPTO Granted Patents = 18

% Expired Patents = 38.9

EPO Patents = 4

Trademarks = 1

Forward Citations = 160

Loading Chart...

Loading Chart...

28 inventors (with patents filed for the assignee):

Alessandro Moretta (9 out of 21 patents)

Francois Romagne (7 out of 12 patents)

Pascale Andre (5 out of 18 patents)

4. Andrea Velardi (3 out of 4 patents)

5. Laurent Gauthier (2 out of 42 patents)

6. Mathieu Blery (2 out of 14 patents)

7. Christian Belmant (2 out of 14 patents)

8. Emanuela Marcenaro (2 out of 2 patents)

9. Mariella Della Chiesa (2 out of 6 patents)

10. Roberta Castriconi (2 out of 2 patents)

11. Christina Bottino (2 out of 2 patents)

12. Lorenzo Moretta (2 out of 4 patents)

13. Roberto Biassoni (2 out of 6 patents)

14. Cristina Bottino (2 out of 5 patents)

15. Ivan Perrot (1 out of 9 patents)

18 patents: Sort by Forward Citations

1. 10577416 - Mica binding agents (2020-03-03),

2. 10160810 - Monoclonal antibodies against NKG2A (2018-12-25),

3. 10059765 - Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds (2018-08-28),

4. 9902936 - PAN-KIR2DL NK-receptor antibodies and their use in diagnostics and therapy (2018-02-27),

5. 9844593 - Methods for treatment of recurrent hematological malignancies (2017-12-19),

6. 9447185 - Compositions and methods for treating proliferative disorders (2016-09-20),

7. 9090876 - Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds (2015-07-28),

8. 9067997 - Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders (2015-06-30),

9. 8993319 - Monoclonal antibodies against NKG2A (2015-03-31),

10. 8637258 - Compositions and methods for regulating NK cell activity (2014-01-28),

11. 8465931 - Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor (2013-06-18),

12. 8017596 - Phosphonates useful as modulators of T-γ-9-δ-2 activity (2011-09-13),

13. 7803376 - Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds (2010-09-28),

14. 7767842 - Class of γδ T cells activators and use thereof (2010-08-03),

15. 7732131 - Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor (2010-06-08),

Company Overview

Innate Pharma S.A. is a biotechnology company based in Marseille, France, specializing in the development of innovative immunotherapies for cancer treatment. The company focuses on harnessing the body's immune system to target and eliminate cancer cells, with a strong emphasis on monoclonal antibodies and immune checkpoint inhibitors. Innate Pharma is dedicated to advancing its proprietary technologies and collaborating with partners to enhance therapeutic options for patients facing various types of cancer.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

18 Patents

#5 in Marseille

#1,097 in France

#34,244 in the World

Marseille, France

Innate Pharma, S.a.

Forward Citations = 160

28 inventors:

Alessandro Moretta (9 out of 21 patents)

Francois Romagne (7 out of 12 patents)

Pascale Andre (5 out of 18 patents)

4. Andrea Velardi (3 out of 4 patents)

5. Laurent Gauthier (2 out of 42 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Innate Pharma, S.a.. Retrieved from https://idiyas.com/company/innate-pharma-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…